We analyzed clinical characteristics (age, sex, IPI factors, response to treatment, event-free survival (EFS) and overall survival (OS))...in newly diagnosed DLBCL patients treated with R-CHOP or similar regimens….BCL2 + patients fared significantly worse if they co-expressed gal-3 (EFS at 2 y 44% vs 73% (p=0,002) OS at 2 y 50% vs 74% (p=0,006))....Our results are in accordance with experimental data indicating that NF-κB stimulates gal-3 expression and that gal-3 potentiates the antiapoptotic effect of BCL2. Gal-3 is more frequently expressed in advanced-stage DLBCLs and those of non-GC subtype, consistent with its putative proliferative/antiapoptotic effect...